Enveric Biosciences (ENVB) Other Non-Current Assets (2015 - 2016)
Enveric Biosciences (ENVB) posted Other Non-Current Assets of $29.4 million for Q4 2016, up 9.64% sequentially from $26.9 million in Q3 2016, and up 342.21% YoY from $6.7 million in Q1 2016.
Enveric Biosciences (ENVB) Other Non-Current Assets (2015 - 2016) Analysis & Trends
Enveric Biosciences has reported Other Non-Current Assets for 2 years, with the latest figure at $29.4 million in Q4 2016.
- Quarterly Other Non-Current Assets rose 342.21% year-over-year to $29.4 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $29.4 million (up 342.21% YoY) and the FY2016 annual result came in at $29.4 million, up 342.21% from the prior year.
- Other Non-Current Assets improved to $29.4 million in Q4 2016 per ENVB's latest filing, from $26.9 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $29.4 million in Q4 2016 and troughed at $3750.0 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 62.96 Mn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | 68,745.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 29.44 Mn |
| Sep 30, 2016 | 26.85 Mn |
| Jun 30, 2016 | 6.92 Mn |
| Mar 31, 2016 | 6.88 Mn |
| Dec 31, 2015 | 6.66 Mn |
| Sep 30, 2015 | 20,587.00 |
| Jun 30, 2015 | 6,250.00 |
| Mar 31, 2015 | 3,750.00 |